What medications are appropriate for an adult patient with anxiety, insomnia, and mild-to-moderate pain?

Medication for Anxiety, Sleep, and Pain

For an adult patient presenting with anxiety, insomnia, and mild-to-moderate pain, duloxetine (60 mg) is the single best medication that addresses all three symptoms simultaneously, with moderate-certainty evidence for pain and sleep benefits, while also treating anxiety as an FDA-approved indication.

Rationale for Duloxetine as First-Line

Duloxetine uniquely addresses the triad of symptoms:

• Pain Management: Duloxetine 60 mg (standard dose) demonstrates small to moderate effects for substantial pain relief (OR 1.91) and continuous pain intensity reduction (SMD -0.31), with moderate-certainty evidence. It consistently ranked as the highest-efficacy antidepressant across all chronic pain outcomes including physical function, sleep, and quality of life 1.

• Anxiety Treatment: Duloxetine is FDA-approved for generalized anxiety disorder and showed small but significant mood improvement effects (SMD -0.16) in pain studies 1. The evidence supports its use in anxiety-related insomnia 2.

• Sleep Benefits: While duloxetine isn't primarily a hypnotic, its anxiolytic and analgesic properties indirectly improve sleep by addressing underlying anxiety and pain that perpetuate insomnia 3, 4.

Critical caveat: Standard dose (60 mg) is as efficacious as higher doses across all outcomes, so avoid unnecessary dose escalation 1.

Alternative Approach: Targeted Combination Therapy

If duloxetine monotherapy proves insufficient or contraindicated, use a targeted two-medication approach:

For Insomnia Component

Based on American Academy of Sleep Medicine guidelines 5:

First-tier options (all WEAK recommendations, meaning clinical judgment required):

• Eszopiclone 2-3 mg: Addresses both sleep onset and maintenance insomnia
• Zolpidem 10 mg: For sleep onset and maintenance
• Low-dose doxepin 3-6 mg: Specifically for sleep maintenance insomnia

Second-tier options:

• Suvorexant: For sleep maintenance issues specifically
• Temazepam 15 mg: For onset and maintenance

Avoid: Trazodone (negative recommendation despite common clinical use), diphenhydramine, melatonin, and tiagabine per guideline evidence 5.

For Pain Component

Per American College of Physicians/AAFP guidelines 6:

Safest effective options:

• Topical NSAIDs: Among most effective for treatment satisfaction with moderate-certainty evidence showing NO significant increase in GI or neurologic adverse events
• Oral NSAIDs: Effective for symptom relief but carry increased GI adverse events (OR 1.77)

Avoid opioids: Acetaminophen plus opioids showed high-certainty evidence for increased neurologic adverse events (OR 3.53) and moderate-certainty evidence for GI adverse events (OR 5.63). Tramadol similarly increases neurologic (OR 6.72) and GI risks 6.

For Anxiety Component

If not using duloxetine:

• Benzodiazepines (e.g., temazepam) can address both anxiety and insomnia but carry dependence risks 2
• Eszopiclone has evidence for anxiety-related insomnia specifically 3, 2

Clinical Decision Algorithm

1. Start with duloxetine 60 mg if all three symptoms (anxiety, insomnia, pain) are moderate-to-severe and patient has no contraindications

2. If insomnia predominates and anxiety/pain are mild:

   • Eszopiclone 2-3 mg OR zolpidem 10 mg
   • Add topical NSAIDs for pain as needed
   • Consider adding duloxetine if anxiety worsens

3. If pain predominates and insomnia/anxiety are mild:

   • Topical NSAIDs first-line
   • Add eszopiclone or low-dose doxepin for persistent insomnia
   • Escalate to duloxetine if pain inadequately controlled

4. If anxiety predominates with secondary insomnia:

   • Duloxetine 60 mg addresses both
   • Alternative: Eszopiclone (has specific evidence for anxiety-related insomnia) 2

Important Pitfalls to Avoid

• Don't use trazodone for insomnia: Despite widespread clinical use, guidelines explicitly recommend against it 5. The evidence for trazodone in insomnia is surprisingly limited despite common prescription patterns 4.

• Don't reflexively choose "sedating" antidepressants: Evidence shows that baseline insomnia or anxiety does NOT predict differential response between sedating (imipramine) versus activating (fluoxetine) antidepressants 7. The sedation profile should not drive antidepressant selection.

• Don't combine acetaminophen with opioids: This combination is "among the most harmful" for both neurologic and GI adverse events 6.

• Don't exceed duloxetine 60 mg: Higher doses provide no additional efficacy but may increase adverse effects 1.

• Screen for substance use history: Patients with past/present substance use disorder have 10.5% absolute risk increase for prolonged opioid use, making opioids particularly dangerous in this population 6.

Monitoring and Duration

• Insomnia medications: Most evidence supports short-term use. Set clear expectations about duration at initiation 8.
• Duloxetine: Monitor for mood improvement (small effect size, so don't expect dramatic changes), pain reduction, and sleep quality over 4-8 weeks.
• NSAIDs: Monitor for GI symptoms if using oral formulations; topical formulations have superior safety profile 6.

The evidence strongly favors duloxetine as a single agent addressing all three symptom domains, with topical NSAIDs and eszopiclone as evidence-based adjuncts when monotherapy proves insufficient.